Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Andrew H. Wei; Hartmut Döhner; Hamid Sayar; Farhad Ravandi; Pau Montesinos; Hervé Dombret; Dominik Selleslag; Kimmo Porkka; Jun Ho Jang; Barry Skikne; C. L. Beach; Thomas Prebet; George Zhang; Alberto Risueño; Manuel Ugidos; Wendy L. See; Daniel Menezes; Gail J. Roboz

doi:10.1002/ajh.26847

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Andrew H. Wei
, Hartmut Döhner
, Hamid Sayar
, Farhad Ravandi
, Pau Montesinos
, Hervé Dombret
, Dominik Selleslag
, Kimmo Porkka
, Jun Ho Jang
, Barry Skikne
, C. L. Beach
, Thomas Prebet
, George Zhang
, Alberto Risueño
, Manuel Ugidos
, Wendy L. See
, Daniel Menezes
, Gail J. Roboz

Department of Internal Medicine

Alfred Health
Monash University
Ulm University
Indiana University Bloomington
University of Texas MD Anderson Cancer Center
Hospital Universitario La Fe
Université Paris Cité
AZ Sint-Jan Brugge-Oostende AV
University of Helsinki
University of Kansas Cancer Center
Bristol-Myers Squibb
Cornell University
New York Presbyterian Hospital

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English
Pages (from-to)	E84-E87
Journal	American Journal of Hematology
Volume	98
Issue number	4
DOIs	https://doi.org/10.1002/ajh.26847
State	Published - Apr 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/ajh.26847

Cite this

Wei, A. H., Döhner, H., Sayar, H., Ravandi, F., Montesinos, P., Dombret, H., Selleslag, D., Porkka, K., Jang, J. H., Skikne, B., Beach, C. L., Prebet, T., Zhang, G., Risueño, A., Ugidos, M., See, W. L., Menezes, D., & Roboz, G. J. (2023). Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. American Journal of Hematology, 98(4), E84-E87. https://doi.org/10.1002/ajh.26847

@article{48e487f251ce463a9c047830ffb20b67,

title = "Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial",

author = "Wei, \{Andrew H.\} and Hartmut D{\"o}hner and Hamid Sayar and Farhad Ravandi and Pau Montesinos and Herv{\'e} Dombret and Dominik Selleslag and Kimmo Porkka and Jang, \{Jun Ho\} and Barry Skikne and Beach, \{C. L.\} and Thomas Prebet and George Zhang and Alberto Risue{\~n}o and Manuel Ugidos and See, \{Wendy L.\} and Daniel Menezes and Roboz, \{Gail J.\}",

year = "2023",

month = apr,

doi = "10.1002/ajh.26847",

language = "English",

volume = "98",

pages = "E84--E87",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc",

number = "4",

}

Wei, AH, Döhner, H, Sayar, H, Ravandi, F, Montesinos, P, Dombret, H, Selleslag, D, Porkka, K, Jang, JH, Skikne, B, Beach, CL, Prebet, T, Zhang, G, Risueño, A, Ugidos, M, See, WL, Menezes, D & Roboz, GJ 2023, 'Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial', American Journal of Hematology, vol. 98, no. 4, pp. E84-E87. https://doi.org/10.1002/ajh.26847

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. / Wei, Andrew H.; Döhner, Hartmut; Sayar, Hamid et al.
In: American Journal of Hematology, Vol. 98, No. 4, 04.2023, p. E84-E87.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy

T2 - Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

AU - Wei, Andrew H.

AU - Döhner, Hartmut

AU - Sayar, Hamid

AU - Ravandi, Farhad

AU - Montesinos, Pau

AU - Dombret, Hervé

AU - Selleslag, Dominik

AU - Porkka, Kimmo

AU - Jang, Jun Ho

AU - Skikne, Barry

AU - Beach, C. L.

AU - Prebet, Thomas

AU - Zhang, George

AU - Risueño, Alberto

AU - Ugidos, Manuel

AU - See, Wendy L.

AU - Menezes, Daniel

AU - Roboz, Gail J.

PY - 2023/4

Y1 - 2023/4

UR - https://www.scopus.com/pages/publications/85147494639

U2 - 10.1002/ajh.26847

DO - 10.1002/ajh.26847

M3 - Letter

C2 - 36655608

AN - SCOPUS:85147494639

SN - 0361-8609

VL - 98

SP - E84-E87

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 4

ER -

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

UN SDGs

Access to Document

Other files and links

Cite this